微小 RNA 作为胃肠癌的生物标志物。
MicroRNA as a Biomarker in Gastroenterological Cancers.
机构信息
Department of Gastroenterology and Neurology, Kagawa University Faculty of Medicine, 1750-1 Ikenobe, Miki 761-0793, Japan.
Department of Gastroenterology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan.
出版信息
Int J Mol Sci. 2022 Apr 24;23(9):4701. doi: 10.3390/ijms23094701.
Abstract
This Special Issue aims to highlight the usefulness of microRNA (miRNA) as diagnostic and prognostic markers of gastroenterological cancer (GC) [...].
摘要
本特刊旨在强调 microRNA（miRNA）作为胃肠癌（GC）诊断和预后标志物的有用性[...]。
相似文献
1
MicroRNA as a Biomarker in Gastroenterological Cancers.微小 RNA 作为胃肠癌的生物标志物。
Int J Mol Sci. 2022 Apr 24;23(9):4701. doi: 10.3390/ijms23094701.
2
MicroRNAs (miRNAs) as biomarker(s) for prognosis and diagnosis of gastrointestinal (GI) cancers.微小RNA（miRNA）作为胃肠道（GI）癌预后和诊断的生物标志物。
Curr Pharm Des. 2014;20(33):5287-97. doi: 10.2174/1381612820666140128213117.
3
Circulating microRNAs as a novel class of diagnostic biomarkers in gastrointestinal tumors detection: a meta-analysis based on 42 articles.循环微RNA作为胃肠道肿瘤检测中一类新型诊断生物标志物：基于42篇文章的荟萃分析
PLoS One. 2014 Nov 18;9(11):e113401. doi: 10.1371/journal.pone.0113401. eCollection 2014.
4
MicroRNA in gastrointestinal cancer: a step closer to reality.胃肠道癌症中的 microRNA：更接近现实。
Adv Clin Chem. 2013;62:221-68. doi: 10.1016/b978-0-12-800096-0.00006-8.
5
Long Non-coding RNA and microRNAs as Novel Potential Biomarker and Therapeutic Target in the Treatment of Gastrointestinal Cancers.长链非编码RNA和微小RNA作为胃肠道癌症治疗中的新型潜在生物标志物和治疗靶点
Curr Pharm Des. 2018;24(39):4599-4600. doi: 10.2174/138161282439190314091937.
6
Circulating microRNAs: potential biomarkers for common malignancies.循环微RNA：常见恶性肿瘤的潜在生物标志物。
Biomark Med. 2015;9(2):131-51. doi: 10.2217/bmm.14.102.
7
Exosomal miR-1246 in body fluids is a potential biomarker for gastrointestinal cancer.体液中的外泌体miR-1246是胃肠道癌症的潜在生物标志物。
Biomark Med. 2018 Oct;12(10):1185-1196. doi: 10.2217/bmm-2017-0440. Epub 2018 Sep 21.
8
Potential role of miR-100 in cancer diagnosis, prognosis, and therapy.miR-100在癌症诊断、预后及治疗中的潜在作用。
Tumour Biol. 2015 Mar;36(3):1403-9. doi: 10.1007/s13277-015-3267-8. Epub 2015 Mar 5.
9
Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract.微小RNA检测在胃肠道神经内分泌肿瘤中的临床应用
Molecules. 2014 Feb 21;19(2):2458-68. doi: 10.3390/molecules19022458.
10
Preface: special issue on microRNAs as novel cancer biomarkers and therapeutic targets.前言：关于微小RNA作为新型癌症生物标志物和治疗靶点的特刊
Crit Rev Oncog. 2013;18(4):v-vi. doi: 10.1615/critrevoncog.2013007195.
引用本文的文献
1
Adherence to STARD guidelines in miRNA diagnostic accuracy studies for hepatocellular carcinoma: a systematic review.肝细胞癌微小RNA诊断准确性研究中对STARD指南的遵循情况：一项系统评价
BMC Med Res Methodol. 2025 Jun 6;25(1):155. doi: 10.1186/s12874-025-02610-5.
本文引用的文献
1
Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer.动态液体活检标志物在结直肠癌中的预测和预后价值。
J Exp Clin Cancer Res. 2022 Mar 15;41(1):99. doi: 10.1186/s13046-022-02318-0.
2
hsa-miR-875-5p inhibits tumorigenesis and suppresses TGF-β signalling by targeting USF2 in gastric cancer.hsa-miR-875-5p 通过靶向 USF2 抑制胃癌的肿瘤发生和 TGF-β 信号通路。
J Transl Med. 2022 Mar 7;20(1):115. doi: 10.1186/s12967-022-03253-6.
3
A microRNA-based liquid biopsy signature for the early detection of esophageal squamous cell carcinoma: a retrospective, prospective and multicenter study.基于 microRNA 的液体活检标志物用于食管鳞癌的早期检测：一项回顾性、前瞻性和多中心研究。
Mol Cancer. 2022 Feb 11;21(1):44. doi: 10.1186/s12943-022-01507-x.
4
Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinoma.转录组谱分析确定了用于预测胰腺导管腺癌患者手术后复发的外泌体 microRNA 特征。
Ann Surg. 2022 Dec 1;276(6):e876-e885. doi: 10.1097/SLA.0000000000004993. Epub 2021 Jun 16.
5
Cancer-Derived Extracellular Vesicle-Associated MicroRNAs in Intercellular Communication: One Cell's Trash Is Another Cell's Treasure.肿瘤细胞外囊泡相关 microRNAs 在细胞间通讯中的作用：一将功成万骨枯。
Int J Mol Sci. 2019 Dec 4;20(24):6109. doi: 10.3390/ijms20246109.
6
MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma.微小RNA-122靶向丝氨酸蛋白酶抑制剂B3并参与肝细胞癌的索拉非尼耐药
J Clin Med. 2019 Feb 1;8(2):171. doi: 10.3390/jcm8020171.
7
MiR-122 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting Snail1 and Snail2 and suppressing WNT/β-cadherin signaling pathway.微小RNA-122通过靶向Snail1和Snail2并抑制WNT/β-连环蛋白信号通路来抑制肝细胞癌中的上皮-间质转化。
Exp Cell Res. 2017 Nov 15;360(2):210-217. doi: 10.1016/j.yexcr.2017.09.010. Epub 2017 Sep 8.
Zotero 插件